Alphatec (NASDAQ:ATEC) Shares Down 3.5% – Time to Sell?

Alphatec Holdings, Inc. (NASDAQ:ATEC) shares fell 3.5% during mid-day trading on Monday . The stock traded as low as $9.71 and last traded at $9.71. 68,184 shares traded hands during trading, a decline of 97% from the average session volume of 1,951,606 shares. The stock had previously closed at $10.06.

Analyst Ratings Changes

Several analysts have commented on the stock. Barclays lifted their target price on shares of Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 19th. Wells Fargo & Company dropped their target price on Alphatec from $26.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Piper Sandler decreased their price target on Alphatec from $17.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Stifel Nicolaus dropped their price objective on shares of Alphatec from $19.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and an average target price of $17.11.

Alphatec Stock Performance

The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The stock has a 50 day moving average of $6.86 and a 200 day moving average of $8.19. The stock has a market capitalization of $1.36 billion, a P/E ratio of -7.51 and a beta of 1.31.

Institutional Trading of Alphatec

A number of large investors have recently modified their holdings of ATEC. Vanguard Group Inc. grew its holdings in Alphatec by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 5,458,847 shares of the medical technology company’s stock worth $75,278,000 after buying an additional 64,648 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Alphatec by 14.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 26,346 shares of the medical technology company’s stock valued at $364,000 after purchasing an additional 3,268 shares during the period. Bayesian Capital Management LP raised its stake in shares of Alphatec by 5.6% during the first quarter. Bayesian Capital Management LP now owns 27,000 shares of the medical technology company’s stock valued at $372,000 after purchasing an additional 1,442 shares in the last quarter. Comerica Bank lifted its holdings in Alphatec by 64.8% in the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after purchasing an additional 2,534 shares during the period. Finally, Cetera Advisors LLC grew its position in Alphatec by 15.6% in the 1st quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock valued at $175,000 after buying an additional 1,720 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.